Amgen’s Playing To Its R&D Strengths, Which No Longer Include Neuroscience
The company will focus on core therapeutics areas like oncology and cardiovascular disease, but left open the possibility of future work in neuroscience with a genetic basis for drug development.
You may also be interested in...
New data show that early-stage Alzheimer’s trials increasingly are sponsored by government and nonprofit organizations, while another review illustrates diversification of the clinical pipeline.
Private Company Edition: China-focused Nuance Pharma led recent venture capital deals with a $181m series D round, RayzeBio closed a $105m series B and SciNeuro launched with $100m plus other notable rounds from Edgewise, Reneo, BioAge and others.
Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.